Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, ...

According to Research by SNS Insider, U.S. Multiple Myeloma Market is projected to reach USD 13.91 Billion by 2032, as novel drug classes, immunotherapies, and diagnostic advances reshape treatment ...

During a live event, Jorge Monge, MD, discussed real-world evidence on the use of CAR T-cell therapy beyond the trial setting ...

PET/CT is a critical tool for MM staging, treatment response monitoring, and the detection of extramedullary disease (EMD), the authors explained. PET/CT has also been found to be a valuable ...

An expert discusses the growing importance of real-world evidence in informing payer decisions and value-based care strategies for bispecific therapies in relapsed/refractory multiple myeloma (R/R MM) ...

Panelists discuss how recent updates from the phase 3 IsKia trial demonstrate that isatuximab combined with carfilzomib, lenalidomide, and dexamethasone improves minimal residual disease negativity ...

Researchers sought to determine whether subcutaneous isatuximab would be effective for patients with newly diagnosed MM who are ineligible for transplantation.

Cancer survival has doubled in the past half a century, but around 167,000 people still die of the disease in the UK every ...

Despite decades of research, multiple myeloma remains an incurable disease. A wide array of therapies, such as proteasome ...

Genmab's (GMAB) stock gains as its lymphoma drug epcoritamab developed with AbbVie (ABBV) succeeds in a Phase 3 lymphoma ...

Giving patients a whole-body MRI scan can detect minuscule amounts of myeloma, also known as minimal residue disease, even ...

A Royal Air Force pilot diagnosed with blood cancer was able to return to flying jets after being given a new scanning ...